Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fibroblast Growth Factor 21 Relieves Lipopolysaccharide-Induced Acute Lung Injury by Suppressing JAK2/STAT3 Signaling Pathway
Mengsi Cai, Huihui Ye, Xiayan Zhu, et al.
Inflammation (2023) Vol. 47, Iss. 1, pp. 209-226
Open Access | Times Cited: 10

Showing 10 citing articles:

Tocilizumab alleviated lipopolysaccharide-induced acute lung injury by improving PI3K/AKT pathway
Junting Weng, Shuoyun Weng, Jing Xu, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 1
A strategy for oral delivery of FGF21 for mitigating inflammation and multi-organ damage in sepsis
Xinze Li, Dedong Yu, Xuanhe Chen, et al.
International Journal of Pharmaceutics (2024) Vol. 656, pp. 124115-124115
Closed Access | Times Cited: 5
Icariside II alleviates lipopolysaccharide-induced acute lung injury by inhibiting lung epithelial inflammatory and immune responses mediated by neutrophil extracellular traps
Xiuchun Li, Yangyue Wang, Yuxin Chen, et al.
Life Sciences (2024) Vol. 346, pp. 122648-122648
Open Access | Times Cited: 5
Hexahistidine-metal assembly encapsulated fibroblast growth factor 21 for lipopolysaccharide-induced acute lung injury
Lanlan Song, Huihui Ye, Zhanghang Lv, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2025), pp. 114650-114650
Closed Access
Research progress and strategy of FGF21 for skin wound healing
Shisheng Lin, Lu Tang, Nuo Xu
Frontiers in Medicine (2025) Vol. 12
Open Access
The STAT3 inhibitor B9 alleviates lipopolysaccharide-induced acute lung injury through its anti-inflammatory effects
Liyue Cao, Huijuan Song, Sheng Zhou, et al.
International Immunopharmacology (2024) Vol. 135, pp. 112221-112221
Closed Access | Times Cited: 1
A Novel Stat3 Ccd Inhibitor for Suppressing Inflammasome Activation in Macrophages and Lipopolysaccharide-Induced Acute Lung Injury
Shangze Yang, Sheng Zhou, Wei Wang, et al.
(2024)
Closed Access
Deleting fibroblast growth factor 2 in macrophages aggravates septic acute lung injury by increasing M1 polarization and inflammatory cytokine secretion
Lingxian Yi, Yu Chen, Yaoyang Zhang, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access
A novel STAT3 CCD inhibitor for suppressing macrophage activation and lipopolysaccharide-induced acute lung injury
Shangze Yang, Sheng Zhou, Wei Wang, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113523-113523
Closed Access
Fibroblast Growth Factor 21 Confers Protection Against Asthma Through Inhibition of NLRP3 Inflammasome Activation
Yudong Liu, Jingxian Li, Zhen-Yu Wu, et al.
Inflammation (2024)
Closed Access
Page 1

Scroll to top